6 taboos about dolopastine/romigrastim

Romiplostim/Romiplostim, as a recombinant humanized protein, is mainly used to treat chronic immune thrombocytopenia (ITP). Its mechanism is to simulate thrombopoietin, stimulate the bone marrow to produce platelets, and reduce the risk of bleeding. However, not all patients are suitable for using this drug, and there are clear clinical contraindications for its use. Before initiating treatment with romiplostim, understanding these contraindications is critical to ensure efficacy, safety, and avoid adverse events.

The first category of contraindications is those who are allergic to this product or any of its ingredients. Patients with allergic reactions that may manifest as rash, shortness of breath, or laryngeal edema should avoid the use of these biologics. The second category is patients with severe active thrombotic disease. Because romigrastim stimulates the rapid rise of platelets, if the patient already has a tendency to thrombosis, it may induce or aggravate vascular embolism events.

Third, patients who have not been diagnosed with chronic ITP but have thrombocytopenia should not use this drug. For patients with secondary thrombocytopenia or other hematological diseases, the causes are complex, and blind use of TPO receptor agonists may aggravate the condition.

The fourth is patients with severely impaired liver function. Although the drug does not depend on liver metabolism, in the state of liver dysfunction, the drug clearance rate may be reduced and the platelet response may be unpredictable. Fifth, pregnant and lactating women should use it with caution. Although animal studies show some embryotoxicity, human data are limited. If it is really necessary to use it, it should be carried out under the evaluation of a doctor. Sixth, there is limited experience in using it in minors. Although there are some studies on pediatric indications abroad, it should still be used with caution in domestic clinical practice.

In summary, although romigrastim has shown good efficacy in the treatment of chronicITP, it is not suitable for all patients. Before starting treatment, a professional doctor should conduct a comprehensive assessment to clarify contraindications, avoid potential risks caused by blind use of medication, and ensure that patients benefit under the premise of safety.

Reference materials:https://en.wikipedia.org/wiki/Romiplostim